Sharing is caring!

Regeneron’s monoclonal antibodies treat SARS-CoV-2 infection in animals.

Regeneron’s monoclonal antibodies developed to target SARS-CoV-2 released a new report evaluating the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters, which may model more severe disease. 

The lead candidate was able to reduce virus load in lower and upper airways and decrease virus-induced pathological sequelae when administered prophylactically or therapeutically in rhesus macaques.

The monoclonal antibody, REGN-COV2 is a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein and is currently in its late-stage clinical trials.

The work is published in Science in the paper titled, “REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.

(Source: GEN News, 2020)

Antengene and WuXi Biologics collaborate to accelerate the research and development of Innovative Oncology Therapies. 

Antengene Corporation and WuXi Biologics have recently signed a strategic Memorandum of Understanding (MoU) for the development and production of novel drugs, and to jointly promote R&D of innovative oncology therapies.

Through the new collaboration, Antengene and WuXi Biologics will make full use of their extensive resources and professional capabilities to accelerate the research and development of innovative cancer therapies and provide patients with high-quality and affordable treatment plans as soon as possible.

Both companies are excited and are looking forward to enhancing the quality of research and development and leveraging complementary strengths of both companies to ultimately benefit a wider range of cancer patients.

(Source: Contract Pharma, 2020)

Sharp invests $10 million in its biologics packaging equipment to support the market.  

Sharp, a global provider of contract packaging and clinical supply services, has invested $10 million in equipment capabilities to directly support client demand in the biologics and injectables market.

The investment includes the installation and validation of two new Dividella NeoTopx packaging systems, for their facility in Allentown, United States, and Hamont-Achel facility in Belgium.

The Dividella system is an automated top-loading cartoner with the flexibility to pack vials, syringes, autoinjectors, and multi-component kits and offers large standardized packaging runs for vaccines. It also supports Sharp’s sustainability initiative due to the full cardboard designs of the packs produced reducing the use of plastic blisters.

The Allentown site will also be installing an NJM Courser 230 Vial and Syringe Labeler offering simple, toolless changeover to reduce downtime between batches, delivering further efficiencies in small-scale production.

(Source: Contract Pharma, 2020)